| ObjectivesTo observe the neuroprotective effects of atorvastin by measuring the the levels of tumor necrosis factor-α(TNF-α) and interleukin-10(IL-10) and the ratio of IL-10/TNF-αin the brain ischemic necrosis tissue of rats.Methods90 healthy male SD rats, weighting from 220g to 240g, were randomly assigned to normal, sham, ischemia and atorvastin therapy groups. And the atorvastin therapy groups according to the different time points of therapy were randomly divided into 3 sub-group (6h before ischemic, simultaneous administration, 6h after ischemic) ,each group have 16 rats except normal group 8 rats and ischemia group 18 rats. The focal cerebral ischemia models of rats were established by using the suture-occluded method of modified Zea Longa. Each sub-group of atorvastin were given atorvastin 10mg/kg at corresponding time point by nasogastric feeding, and the other two sub-groups were given same dose of saline solution instead. While,the sham group and the ischemia group were given the same dose of saline solution at each time points.The neurological deficits of rats were evaluated by Bederson's method. The cerebral infarct size were analyzed by using 2,3,5- triphenyl tetrazolium chloride(TTC) staining. The levels of TNF-αand IL-10 in the brain ischemic necrosis tissue were detected by enzyme linked immunosorbent assay techniques. Calculate the ratio of IL-10/TNF-αand investigate the relationship between the ratio of IL-10/TNF-αand the cerebral infarct volumes. The datas were analyzed by using a statistical software SPSS 13.0.Results1.Evaluation of neurological deficits: No neurological deficit symptoms were found in the normal and sham groups; However, both the ischemia and atorvastin groups were exhibited with obvious neurological deficit symptoms, and Bederson's scores of measuring neurological deficit of the ischemia group and atorvastin group were significantly higher when compared with the sham group (P﹤0.01). And the Bederson's scores of the group treated with atorvastin 6h before ischemia or simultaneous administration were significantly decreased when compared with the ischemia group(P﹤0.01).2. TTC staining: The TTC brain staining of sham group were symmetrical red areas, while both the ischemia and atorvastin groups were seen with obvious white infarct areas. Compared with the ischemia group ,the infarct size of the group treating with atorvastin 6h before or simultaneous administration were significantly smaller (P﹤0.01).3.Enzyme linked immunosorbent assay: The levels of TNF-αand IL-10 of rat brains between the normal group and sham group had no change, Compared with the rats of sham group's the levels of TNF-αand IL-10 of ischemia group's were significantly increased(P﹤0.01); Compared with ischemia group's rats, the levels of TNF-αwere significantly decreased(P﹤0.01)and the IL-10 were significantly increased(P<0.01)in the brain organizations of treated with atorvastin 6h before ischemia group and simultaneous administration group, as well as the ratio of IL-10/ TNF-αwere improved clearly.Conclusions1. After ischemia the ratio of IL-10/ TNF-αwere declined significantly. there was a notable negative correlation between the ratio of IL-10/ TNF-αand ischemia volume. 2. Rats treated with atorvastin 6h before ischemia or simultaneous administrative had significant neuroprotections by improving the ratio of IL-10/ TNF-α. |
